Health Condition 1: C569- Malignant neoplasm of unspecifiedovary Health Condition 2: C569- Malignant neoplasm of unspecifiedovary
Conditions
Interventions
None listed
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients with stages III C and IV A (new FIGO classification) serous epithelial ovarian, fallopian tube and primary peritoneal cancer 2. Age between 18-75 years 3. ECOG performance status of >2, ASA 1 or 2 4. Histologically/cytologically proven ovarian, fallopian tube or primary peritoneal carcinoma 5. In case the diagnosis is made on cytology, mullerian origin is confirmed by immunohistochemistry or other primary sites are ruled out by appropriate investigations (colonoscopy, upper GI scopy, ratio of CA-125 to CEA >25.) 6. Laboratory values: serum creatinine 3.5 x 109/l; platelets > 100 x 109 /l
Exclusion criteria
Exclusion criteria: 1. Patient refusing to consent 2. Patients with non-serous histologies like endometroid adenocarcinoma, mucinous carcinoma, clear cell carcinoma and other rare histologies 3. Patients with distant organ metastases like liver and lung metastases 4. Patients who do not undergo both surgery and chemotherapy Patients who develop disease progression on chemotherapy (evaluated according to the RECIST criteria)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) and Overall survival (OS) Timepoint: 6 months 18 months 3 years 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 90-day morbidity and mortality Comparison of total and selective perionectomy Benefit of HIPEC in addition to complete cytoreductive surgeryTimepoint: 1. 30 days following surgery 2. 90 days following surgery 3. 6 months 4. 18 months 5. 3 years 6. 5 yearsa | — |
Countries
India
Contacts
Public ContactDipal Patel
Zydus Hospital
Outcome results
None listed